Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15603211 | 0.83 | GGT1 (0.31) | ARG1ARG2GAATSHR | |
| SCHEMBL13323585 | 0.79 | ALDH1A1 (0.35) | ALDH1A1GAATSHR | |
| SCHEMBL7031959 | 0.79 | LMNA (0.38) | ALDH1A1GAATSHRCYP2D6CYP2C19 | |
| SCHEMBL1739828 | 0.79 | LMNA (0.38) | ALDH1A1GAATSHRCYP2D6CYP2C19 | |
| SCHEMBL11337371 | 0.76 | TET2 (0.41) | ARG1ARG2ALDH1A1GAATSHR | |
| SCHEMBL7262162 | 0.76 | TSHR (0.35) | ALDH1A1GAATSHRCYP2D6CYP2C19 | |
| SCHEMBL5054085 | 0.76 | ACLY (0.43) | ARG1ARG2ALDH1A1TSHRCYP2D6 | |
| SCHEMBL1930752 | 0.76 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| Ammonia Solution, Strong SCHEMBL28055047 | 0.74 | ACLY (0.42) | ARG1ARG2ALDH1A1TSHRPPARA | |
| SCHEMBL7696692 | 0.74 | MAPK1 (0.33) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343968-B2 | Case of renin inhibitors | MERCK CANADA INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | REN, ACE, AGTR1 | ARG1 633/4885ARG2 662/4885ALDH1A1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.